Comparison of daily megavoltage electronic portal imaging or kilovoltage imaging with marker seeds to ultrasound imaging or skin marks for prostate localization and treatment positioning in patients with prostate cancer.
OBJECTIVE
To compare the accuracy of imaging modalities, immobilization, localization, and positioning techniques in patients with prostate cancer.


METHODS
Thirty-five patients with prostate cancer had gold marker seeds implanted transrectally and were treated with fractionated radiotherapy. Twenty of the 35 patients had limited immobilization; the remaining had a vacuum-based immobilization. Patient positioning consisted of alignment with lasers to skin marks, ultrasound or kilovoltage X-ray imaging, optical guidance using infrared reflectors, and megavoltage electronic portal imaging (EPI). The variance of each positioning technique was compared to the patient position determined from the pretreatment EPI.


RESULTS
With limited immobilization, the average difference between the skin marks' laser position and EPI pretreatment position is 9.1 +/- 5.3 mm, the average difference between the skin marks' infrared position and EPI pretreatment position is 11.8 +/- 7.2 mm, the average difference between the ultrasound position and EPI pretreatment position is 7.0 +/- 4.6 mm, the average difference between kV imaging and EPI pretreatment position is 3.5 +/- 3.1 mm, and the average intrafraction movement during treatment is 3.4 +/- 2.7 mm. For the patients with the vacuum-style immobilization, the average difference between the skin marks' laser position and EPI pretreatment position is 10.7 +/- 4.6 mm, the average difference between kV imaging and EPI pretreatment position is 1.9 +/- 1.5 mm, and the average intrafraction movement during treatment is 2.1 +/- 1.5 mm.


CONCLUSIONS
Compared with use of skin marks, ultrasound imaging for positioning provides an increased degree of agreement to EPI-based positioning, though not as favorable as kV imaging fiducial seeds. Intrafraction movement during treatment decreases with improved immobilization.
Serago
Christopher F
CF
Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL 32224, USA. serago.christopher@mayo.edu
Buskirk
Steven J
SJ
Igel
Todd C
TC
Gale
Ashley A
AA
Serago
Nicole E
NE
Earle
John D
JD
D006046:Gold; D006801:Humans; D007103:Immobilization / Q000379:methods; D007259:Infrared Rays; D007834:Lasers; D008297:Male; D009068:Movement; D011467:Prostate / Q000000981:diagnostic imaging; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D019736:Prostheses and Implants; D011859:Radiography; D050397:Radiotherapy, Intensity-Modulated; D012867:Skin / Q000033:anatomy & histology; D014463:Ultrasonography
D006046:Gold